David Lawrence Departs as CFO; Appointed to Board of DirectorsATLANTA, Jan. 9, 2024 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries including stroke and traumatic brain injury, today announced the appointment of William Fricker, CPA, MBA, to Chief Financial Officer, effective immediately.

大卫·劳伦斯（DavidLawrence）辞去首席财务官职务；2024年1月9日，亚特兰大/新闻通讯社/--NeuroTrauma Sciences，LLC（NTS）被任命为董事会成员，这是一家私营生物制药公司，开发用于治疗中枢神经系统（CNS）损伤（包括中风和创伤性脑损伤）的神经保护疗法，今天宣布任命MBA注册会计师威廉·弗里克为首席财务官，立即生效。

In this position, Mr. Fricker will assume responsibility for the oversight of NTS's financial strategy and operations..

在这个职位上，弗里克先生将负责监督NTS的财务战略和运营。。

Continue Reading

继续阅读

David Lawrence has stepped down from the full-time CFO position at NeuroTrauma Sciences. He will remain as a consultant and has been appointed to the Board of Directors.

大卫·劳伦斯（DavidLawrence）辞去了NeuroTrauma Sciences的全职首席财务官职位。他将继续担任顾问，并被任命为董事会成员。

NeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial Officer

NeuroTrauma Sciences任命MBA注册会计师威廉·弗里克（WilliamFricker）为首席财务官

Post this

发布此

Mr. Fricker brings to NTS more than 25 years of financial expertise across industries, including pharmaceutical and biotechnology companies, most recently as Chief Financial Officer for Eleison Pharmaceuticals and NeuroRx. In addition, he served as Vice President, Finance & Principal Accounting Officer for Immunomedics, where he supported the transition from a clinical-stage organization to a fully commercial biopharmaceutical company through its acquisition by Gilead in 2020.

弗里克先生为NTS带来了超过25年的跨行业财务专业知识，包括制药和生物技术公司，最近担任Eleison Pharmaceuticals和NeuroRx的首席财务官。此外，他还担任Immunomedics的财务副总裁兼首席会计官，通过2020年被吉利德收购，支持从临床阶段组织过渡到完全商业化的生物制药公司。

There he also managed over $600 million in equity raises. Earlier in his career, he held finance and accounting positions at Johnson & Johnson Corporation and Bristol-Myers Squibb Company, as well as Coopers & Lybrand.  Mr. Fricker holds a Bachelor of Science in Accounting from Penn State University and a Master of Business Administration from Villanova University.

在那里，他还管理了6亿多美元的股权融资。在职业生涯早期，他曾在强生公司、百时美施贵宝公司以及Coopers&Lybrand担任财务和会计职位。弗里克先生拥有宾夕法尼亚州立大学会计学学士学位和维拉诺瓦大学工商管理硕士学位。

He is a Certified Public Accountant..

他是一名注册会计师。。

'NTS is developing neuroprotective compounds in the critically underserved areas of stroke and traumatic brain injury, and I am honored to join the company and leverage my expertise to contribute to its success,' said Mr. Fricker. 'I look forward to partnering with the team to execute on its strategy and help realize the potential of investigational drug NTS-104.''Throughout Bill's significant industry tenure, he has improved financial discipline and supported the finance and operational functions of companies at all stages,' said Carl Long, Chief Executive Officer.

弗里克说，NTS正在中风和创伤性脑损伤等服务严重不足的领域开发神经保护化合物，我很荣幸加入该公司，并利用我的专业知识为其成功做出贡献我期待着与团队合作，执行其战略，并帮助实现研究药物NTS-104的潜力。“在比尔的重要行业任期内，他改进了财务纪律，并在各个阶段支持了公司的财务和运营职能，”首席执行官卡尔·朗（Carl Long）说。

'We are pleased to welcome him to our executive leadership team at an important time in the company's growth.'Mr. Long continued, 'We also thank Dave Lawrence for his contributions to NTS, for his strategic leadership and integrity in the financial management of the company, and we look forward to continue working with him in another capacity.'About NeuroTrauma Sciences NeuroTrauma Sciences is a biopharmaceutical company advancing its mission to develop neuroprotective therapies for treating CNS injuries, including ischemic stroke and traumatic brain injury (TBI).

“在公司成长的重要时刻，我们很高兴欢迎他加入我们的高管团队。”龙先生继续说，“我们也感谢戴夫·劳伦斯（DaveLawrence）对NTS的贡献，感谢他在公司财务管理方面的战略领导和正直，我们期待着以另一种身份继续与他合作。”关于NeuroTrauma Sciences NeuroTrauma Sciences是一家生物制药公司，致力于开发用于治疗中枢神经系统损伤（包括缺血性中风和创伤性脑损伤（TBI））的神经保护疗法。

Acquired brain injuries remain areas of high unmet need with limited therapeutic options to alleviate the cognitive, functional, and neurobehavioral effects for millions of patients worldwide. By leveraging insights into the biology of acquired brain injury, NTS is advancing a pipeline of candidates targeting ischemic stroke and TBI.

获得性脑损伤仍然是高度未满足需求的领域，有限的治疗选择可以缓解全球数百万患者的认知，功能和神经行为影响。通过利用对获得性脑损伤生物学的见解，NTS正在推进一系列针对缺血性中风和TBI的候选药物。

For additional information, please visit www.neurotraumasciences.com. Contacts:NeuroTrauma SciencesWilliam Fricker, CPA, MBA Chief Financial Officer M: 215-622-7875 [email protected]SMP CommunicationsSusan PietropaoloM: 201-923-2049[email protected]SOURCE NeuroTrauma Sciences, LLC.

有关更多信息，请访问www.neurotraumasciences.com。联系人：NeuroTrauma SciencesWilliam Fricker，CPA，MBA首席财务官M:215-622-7875[电子邮件保护]SMP通信Susan PietropaoloM:201-923-2049[电子邮件保护]SOURCE NeuroTrauma Sciences，LLC。